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Abstract
Background: Rift Valley fever virus (RVFV) causes disease in livestock and humans. It can be transmitted by mosquitoes,
inhalation or physical contact with the body fluids of infected animals. Severe clinical cases are characterized by acute
hepatitis with hemorrhage, meningoencephalitis and/or retinitis. The dynamics of RVFV infection and the cell types infected
in vivo are poorly understood.
Methodology/Principal Findings: RVFV strains expressing humanized Renilla luciferase (hRLuc) or green fluorescent protein
(GFP) were generated and inoculated to susceptible Ifnar1-deficient mice. We investigated the tissue tropism in these mice
and the nature of the target cells in vivo using whole-organ imaging and flow cytometry. After intraperitoneal inoculation,
hRLuc signal was observed primarily in the thymus, spleen and liver. Macrophages infiltrating various tissues, in particular
the adipose tissue surrounding the pancreas also expressed the virus. The liver rapidly turned into the major luminescent
organ and the mice succumbed to severe hepatitis. The brain remained weakly luminescent throughout infection. FACS
analysis in RVFV-GFP-infected mice showed that the macrophages, dendritic cells and granulocytes were main target cells
for RVFV. The crucial role of cells of the monocyte/macrophage/dendritic lineage during RVFV infection was confirmed by
the slower viral dissemination, decrease in RVFV titers in blood, and prolonged survival of macrophage- and dendritic cell-
depleted mice following treatment with clodronate liposomes. Upon dermal and nasal inoculations, the viral dissemination
was primarily observed in the lymph node draining the injected ear and in the lungs respectively, with a significant increase
in survival time.
Conclusions/Significance: These findings reveal the high levels of phagocytic cells harboring RVFV during viral infection in
Ifnar1-deficient mice. They demonstrate that bioluminescent and fluorescent viruses can shed new light into the
pathogenesis of RVFV infection.
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Introduction
Rift Valley fever virus (RVFV) is an arthropod-borne member
of the Bunyaviridae family, genus Phlebovirus that causes recurrent
outbreaks affecting humans and animals. The virus can be
transmitted by Aedes and Culex mosquitoes [1], although it can also
be transmitted by inhalation or physical contact with the body
fluids from infected animals [2,3]. Identified in the 1930s in
Kenya, RVFV has spread during recent years to most sub-
Saharan African countries, in Egypt and in the Arabian Peninsula,
and in the Indian Ocean islands of Grande Comore and Mayotte
[4,5,6]. In humans, RVFV infections are generally either
asymptomatic or characterized by a feverish syndrome without
any severe sequelae. However, a small percentage of patients
exhibit complications, characterized by acute hepatitis with
hemorrhage, meningoencephalitis and/or retinitis [7,8,9,10]. A
relationship has been demonstrated between high viral load in
blood and death of the patient [11,12]. RVFV infects domestic
ruminants, including sheep, cattle, goats, and camels. It is
responsible for massive abortion events in pregnant ruminants
and high mortality in lambs and calves. High viremia associated
with hepatic necrosis and increase of liver enzymes are hallmarks
of severe acute lethal infection in ruminants [13,14]. Encephalo-
myelitis has been described in calves [15]. Laboratory rodents such
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as mice are also highly susceptible to RVFV infection. In outbred
Swiss mice, the survival time was inversely proportional to the
logarithm of the viral dose inoculated via the intravenous route
[16]. Depending on their genotype, males from various inbred
strains of mice inoculated by the peritoneal route with 102 PFU of
the virulent Egyptian ZH548 strain die between 4 to 10 days after
inoculation, illustrating natural variation in susceptibility of the
host to RVF [17]. The main damages of mouse infection with
RVFV can be observed early in the liver, with extensive apoptosis
of hepatocytes, accompanied in the blood by a peak in liver
enzymes, along with increased bilirubin levels [18,19,20]. It has
been recently shown that mice that survive hepatitis develop later
infection of the brain, and eventually die from meningoenceph-
alitis [21]. Interestingly, a diverse set of cell types from a number of
tissues was found to contain RVFV antigens, including mononu-
clear phagocytes, but also cardiac myofibers, pancreatic islet cells,
and adrenal medullary cells [21]. These data showed that RVFV
exhibits a large tropism for a variety of tissues and individual cell
types. Quantitative real-time PCR have also been used to study
the kinetics of RVFV infection in the blood and organs of infected
mice [22]. High amounts of RVFV RNA were found in blood,
liver and brain samples shortly after infection with the highest viral
RNA levels in the liver. We hypothesized that in vivo imaging
might be an alternative method to assess viral replication using a
recombinant RVFV carrying a reporter gene that allows the
monitoring of viral expression in live animal.
RVFV has a tripartite negative-sense, single-stranded RNA
genome with large (L), medium (M) and small (S) segments. The L
segment encodes the viral RNA-dependent RNA polymerase, the
M segment the two virion glycoproteins (GN and GC) and the
NSm nonstructural proteins, and the S segment the N nucleo-
protein and the NSs nonstructural protein. Reverse genetic
systems have been successfully developed for the recovery of
recombinant RVFV (reviewed in [23]). These rescue systems rely
on transfection with plasmids expressing the three viral RNAs, and
the N nucleoprotein and L RNA-dependent RNA polymerase,
which are required for the packaging and replication of the viral
RNAs. The RVFV RNA genome segments are expressed under
the control of either the cellular DNA-dependent RNA polymer-
ase I promoter [24,25,26] or the bacteriophage T7 promoter in
cells that constitutively express T7 RNA polymerase [24]. Such
rescue systems have been used to produce recombinant RVFV,
including various mutants that lack the NSs, NSm genes, or carry
specific mutations [26,27,28,29,30]. Viral strains that express
reporter genes were also generated [24,31,32]. Importantly, in
these recombinant viruses, the reporter gene activity directly
reflects the extent of both viral transcription and replication.
In this study, we aimed to detect and quantify viral replication
in living animals using two recombinant RVFV strains expressing
either humanized version of the luciferase gene of Renilla reniformis
(hRLuc) or enhanced green fluorescent protein (GFP) gene of
Aequora victoria. Both RVFV viruses lack a functional NSs gene,
which is a main factor of virulence in mice [33], and are therefore
avirulent in immunocompetent mice. However, in mice that are
nonresponsive to type I IFN, the virus expressing either hRLuc or
GFP caused lethality within 3 days, in agreement with previous
data for the NSs-deficient Clone 13 [24]. In these mice, virus
infection could be tracked by luciferase imaging in live animals
and by the detection of GFP-positive cells from infected animals,
by use of flow cytometry. We observed qualitative and quantitative
differences in the in vivo tropism of RVFV in mice and show
previously unsuspected sites of virus replication and modes of virus
spread.
Methods
Mice, cells and virus
Animals were housed in the Institut Pasteur animal facilities
accredited by the French Ministry of Agriculture to perform
experiments on live mice, in appliance of the French and
European regulations on care and protection of the Laboratory
Animals (accreditation number B 75 15-01 and B 75 15-07). The
veterinary staff of the Institut Pasteur animal facility approved
protocols. Protocols were performed in compliance with the NIH
Animal Welfare Insurance #A5476-01 issued on 02/07/2007.
Inbred 129S2/SvPas mice with knockout at the interferon a and b
receptor 1 locus (Ifnar12/2) and control mice (Ifnar1+/+) were bred
at the Institut Pasteur [34]. Vero E6 cells were grown in DMEM
supplemented with 10% FCS. BHK21/T7 cells [35] were grown
in MEM supplemented with 5% FCS and tryptose phosphate
broth powder (Sigma-Aldrich, Gillingham, UK). The cell culture
media were supplemented with 10 IU/ml of penicillin and 10 mg/
ml of streptomycin. Stocks of the virulent RVFV Egyptian ZH548
strain were produced under biosafety level 3 (BSL3) conditions.
Production of recombinant RVFV strains
Plasmids pPol I-LZH, pPol I-MZH, and pPol I-SZH carrying
the L, M and S segments of ZH548, respectively, were cloned in
the plasmid pRF108, [24,36]. The plasmid pPol I-SZHDNSs,
derived from pPol I-SZH, carries two BbsI cloning sites in place of
NSs [24]. The humanized Renilla reniformis luciferase sequence
from phRL-SV40 (Promega, Charbonnie`res-les-Bains, France)
was inserted in pPol I-SZHDNSs to give pPol I-SZHDNSs-hRLuc.
The structure of pPol I-SZHDNSs-hRLuc plasmid was confirmed
by sequence analysis. Recombinant rZHDNSs-GFP [24] and
rZHDNSs-hRLuc RVFV stocks were produced under BSL3
conditions. Approximately 56105 BHK21/T7 cells were seeded
in triplicate in 35 mm culture dishes. The following day, they were
combined with FuGENEH6 transfection reagent (Roche Applied
Science, Indianapolis, IN) and 0.5 mg each of pTM1-L and
pTM1-N [25], and 1 mg each of pPol I-LZH, pPol I-MZH, and
either pPol I-SZHDNSs-GFP or pPol I-SZHDNSs-hRLuc in
OptiMEM (Gibco, invitrogen, Carslbad, CA). One day later, the
medium was renewed. Five days later, the supernatant containing
the rescued virus was collected and stored at 280uC. To produce
Author Summary
Rift Valley fever, caused by a member of the Bunyaviridae
family, has spread during recent years to most sub-Saharan
African countries, in Egypt and in the Arabian peninsula.
The virus can be transmitted by insect vectors or by direct
contacts with infectious tissues. The analysis of virus
replication and dissemination in laboratory animals has
been hampered by the need to euthanize sufficient
numbers of animals and to assay appropriate organs at
various time points after infection to evaluate the viral
replication. By following the bioluminescence and fluores-
cence of Rift Valley fever viruses expressing light reporters,
we were able to track the real-time dissemination of the
viruses in live immunodeficient mice. We showed that the
first infected organs were the thymus, spleen and liver, but
the liver rapidly became the main location of viral
replication. Phagocytes also appeared as important
targets, and their systemic depletion by use of clodronate
liposomes decreased the number of viruses in the blood,
delayed the viral dissemination and prolonged the survival
of the infected mice.
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viral stocks of rZHDNSs-GFP and rZHDNSs-hRLuc, Vero E6
cells were infected with the rescued virus at a MOI of 0.001 and
0.01, respectively. At 72 h post-infection, the supernatant was
collected and the viral suspension was titered.
Virus titration by plaque assay
Vero E6 cells, infected with serial dilutions of viral suspension,
were incubated under an overlay of DMEM supplemented with
2% FCS, antibiotics and 1% agarose. Four days later, the plates
were stained with 0.2% crystal violet in 10% formaldehyde, 20%
ethanol and the lytic plaques were counted.
hRLuc expression analysis in vitro
To test the luciferase expression within cells after infection with
rZHDNSs-hRLuc, Vero E6 cells were infected using a MOI of 0.3
and 3. Next, every 2 h, for 12 h, luciferase activity was measured
in triplicates by Renilla Luciferase Assay System (Promega,
Madison, WI). To check the stability of luciferase expression
through passages, Vero E6 cells were infected using an MOI of 3
and the luciferase activity was measured in triplicates at 8 h post-
infection.
GFP and viral expression analysis in vitro
To test the GFP expression, Vero E6 cells were infected with
rZHDNSs-GFP using a MOI of 1. At 15 h post-infection, the cells
were fixed for 30 min at room temperature with 4% paraformal-
dehyde in PBS, permeabilized for 10 min with 0.5% Triton X100
in PBS and incubated for 30 min at room temperature in 5%
bovine serum albumin (BSA) in PBS. The cells were next
incubated for 30 min at 37uC with a mouse anti-N antibody
diluted in 5% BSA in PBS (dilution 1:800), washed with 5% BSA
in PBS and incubated for 25 min at 37uC with the secondary
antibody Alexa Fluor 555 goat anti-mouse (Invitrogen, Paisley,
UK) diluted in 5% BSA in PBS (dilution 1:1200). Finally, the cells
were washed with 5% BSA in PBS and then in water. The slides
were mounted with Fluoromont-G (SouthernBiotech, Birming-
ham, AL). The cells were observed under an Axioplan 2 Imaging
microscope (Zeiss, Le Pecq, France) using excitation and emission
filter allowing simultaneous detection of GFP and Alexa Fluor 555.
Infection of mice and monitoring
One week prior to infection, five to six week-old mice were
transferred in BSL3 isolators to allow acclimatization. After this
period, they were inoculated intraperitoneally (i.p.), intradermally
(i.d.) or intranasally with 104 PFU ZH548, rZHDNSs-hRLuc or
rZHDNSs-GFP RVFV in DMEM supplemented with 2% FCS,
and antibiotics. For i.p. infection, mice were inoculated with
100 mL of viral suspension. For i.d. and intranasal infections, mice
were first anesthetized with ketamine (150 mg/kg) and xylazine
(10 mg/kg) administered i.p., then inoculated with either 15 to
30 mL or 15 mL of viral suspension into the ear (i.d.) or
intranasally, respectively. Mortality was recorded at least twice a
day from day 1 to 4 post-infection and once a day after day 5 post-
infection until the end of the observation period. Animals were
observed for a maximum of 14 days.
In vivo bioluminescence imaging
To improve bioluminescence imaging, hairs were removed [37].
We observed the mice to detect clinical signs due to the infection
prior to imaging. Mice that exhibited no severe clinical signs were
anesthetized and injected i.p. with 100 mL h-coelenterazine
(1 mg/ml). The h-coelenterazine stock solution provided by
Nanolight Technology (Pinetop, AZ) was solubilized in ethanol-
propylene glycol solution (1:1) at 10 mg/ml. This solution was
diluted in PBS (1:9) just before imaging. The h-coelenterazine-
treated mice were immediately placed in a hermetically sealed
light-tight-transparent chamber (TEM Sega, Lormont, France)
equipped with two HEPA filters. One HEPA filter was connected
to an air pump, thus allowing air renewal during the imaging. The
bio containment chamber allowed simultaneous imaging of 6
mice. The mice were imaged 15 and 20 min after h-coelenterazine
injection for the whole body and the thorax, respectively [38].
Imaging was performed with a Xenogen’s IVIS 100 system,
including a cooled charge-coupled device (CCD) camera [39,40].
Integration periods ranged from 0.5 to 120 s depending on the
amounts of light emitted at various infection sites. Images were
obtained using Living ImageH 3.1 software (Xenogen, Alameda,
CA). Specific regions of interest (ROI) on the images were defined
without overlay, using the anatomic location of the different
organs and their visual observation through the skin when
possible. For each imaging session, a mock-infected mouse was
used as a negative control. A signal was considered significant if its
intensity in infected mice was at least twofold higher than the
background luminescence in the mock-infected mouse. After the
last imaging time point, mice were euthanized.
Ex vivo bioluminescence imaging
For ex vivo imaging, selected mice were euthanized at different
times after infection for harvest of the following organs: liver,
spleen, thymus, lung, kidney, stomach, small and large intestine,
heart, ovary and uterus, testis, epididymis, seminal vesicles and
preputial glands. The organs were placed in 6 (intestine) or 2 ml
(all other organs) of PBS. Before imaging, 1 mL/ml h-coelenter-
azine 5 mM in ethanol and propylene glycol (1:1) was added [41].
Imaging was performed in a hermetically sealed chamber to avoid
light. Images were acquired 10 min after the addition of h-
coelenterazine. Integration period ranged from 0.5 to 60 s
depending on the amounts of light emitted from various organs.
RNA extraction and quantitative RT-PCR
RNA was extracted using Trizol LS reagent (Invitrogen,
Carslbad, CA) and suspended in RNase free water. RNA was
quantified using Nanodrop 3300 (Thermo Scientific, Courtaboeuf,
France). The M segment of RVFV was amplified with primers 59-
CATGGATTGGTTGTCCGATCA-39 and 59-TGAGTGTAA-
TCTCGGTGGAAGGA-39. Quantitative RT-PCR assays were
performed using StepOne Plus Real-Time PCR System (Applied
Biosystem, Courtaboeuf, France) in 96-well plates. Reverse
transcription using MultiScribe Reverse Transcriptase (Applied
Biosystem) at 48uC for 30 min was performed followed by a
standard amplification program. The size of the amplification
product was 108 pb. A standard curve was generated using
duplicates of 10-fold serial dilutions of RNA of the M segment
ranging from 109 to 102 copies. Quantification of viral RNA was
done by comparison of the threshold cycle (Ct) values of the
samples to the standards.
Histopathological analysis
Histopathological and immunohistochemical analysis of wild-
type mice infected with 104 PFU ZH548 RVFV was performed 3
to 5 days after i.p. inoculation. rZHDNSs-hRLuc-infected Ifnar12/2
mice were euthanized at 8, 16 and 34 h after i.p. inoculation. For
each time point, a complete post-mortem examination was carried
out. The lung, brain, kidneys, spleen, liver, pancreas, thymus, testis,
uterus and ovaries were removed and immediately fixed for one
week in 10% neutral buffered formalin. Samples from each organ
were embedded in paraffin and five-micrometer sections were then
Bioluminescence Imaging in Rift Valley Fever
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cut and stained with hematoxylin and eosin (HE). The histological
characterization of lesions was completed by an immunohisto-
chemical detection of the RVFV using mouse antibodies against the
RVFV (dilution 1:100) visualized with the Histofine Simple Stain
MAX-PO kit (Histofine Biosciences inc, Cambridge, UK).
Flow cytometric analysis
Eleven Ifnar1-deficient 129S2/SvPas mice were either
infected i.p. with 104 PFU rZHDNSs-GFP RVFV (N = 6) or
mock-infected (N = 5). Twenty-four hours later, the spleen was
harvested. Erythrocytes were lysed using NH4Cl (9 g/L)
buffer. The rat anti-mouse CD16/CD32, clone 2.4G2
antibody (BD Pharmingen, San Jose´, CA) was used to block
non-antigen-specific binding of immunoglobulins to Fc-recep-
tors. Cells were stained using a combination of the following
antibodies: (i) PE-conjugated rat anti-mouse NKp46/CD335
(BD Pharmingen). (ii) PerCP-Cy5.5-conjugated hamster anti-
mouse CD3 (BD Pharmingen). (iii) APC-conjugated rat anti-
CD19 (BD Pharmingen). (iv) Pacific Blue-conjugated rat anti-
mouse CD11b/Mac-1 (eBioscience, San Diego, CA). (v) APC-
conjugated hamster anti-mouse CD11c/Itgax (BD Pharmin-
gen). (vi) Alexa Fluor 700-conjugated rat anti-mouse MHC
Class II (I-A/I-E) (eBioscience). (vii) PE-conjugated rat anti-
mouse Ly6G/Gr-1 (BD Pharmingen). (viii) Biotin-conjugated
anti-mouse CD115/c-Fms (eBioscience) with Streptavidin-
PerCP-Cy5.5 (BD Pharmingen) as second-step reagent. All
staining procedures were conducted on ice. Then, the cells
were fixed with 4% formaldehyde. Fluorescence was measured
using a FACSAria II flow cytometer (BD Biosciences, San Jose,
CA), and data analysis was performed using CellQuest (BD
Biosciences) and FlowJo (Ashland, OR) softwares. Dead cells
were visualized using the Fixable Aqua Dead Cell Stain kit
(Invitrogen, Carlsbad, CA). Fluorescence compensation set-
tings for multicolor flow cytometric analysis were optimized
based on single-stained polystyrene microparticles (Comp-
Beads, BD Pharmingen).
Liposome treatment
Clodronate (Cl2MBP; dichloromethylene-biphosphonate)-load-
ed liposomes (CLL) were used to deplete phagocytic cells [42,43].
Clodronate was a gift of Roche Diagnostics GmbH, (Mannheim,
Germany). It was encapsulated in liposomes as described earlier
[42,43]. Mice were injected i.p. with 300 mL and i.v. with 200 mL
CLL. Control mice were treated i.p. and i.v. with PBS-loaded
liposomes. Twenty-four hours later, single-cell suspensions were
prepared from blood and spleen. FcR blocking reagent mouse
(Miltenyi Biotec, Bergisch Gladbach, Germany) was used to block
non-antigen-specific binding of immunoglobulins to Fc-receptors.
Cells were stained using combination of the following antibodies:
FITC-conjugated rat anti-mouse CD11b (BD Pharmingen), PE-
conjugated rat anti-mouse CD115 (eBioscience.com), APC-
conjugated rat anti-mouse F4/80 (eBioscience.com), PE-conjugat-
ed hamster anti-mouse CD11c (BD Pharmingen) and Pacific Blue-
conjugated rat anti-mouse Ly6G/Gr-1 (eBioscience.com). All
staining procedures were conducted on ice. Fluorescence data
were obtained and analyzed using MACSQuant Analyzer and
MACSQuantify software (Miltenyi Biotec). Challenge with
104 PFU rZHDNS-hRLuc was performed by injection into the
ear, 24 h after liposome treatment.
Statistical analysis
The survival curves were compared using the logrank test. The
bioluminescence signals and blood plasma viral loads were
analyzed with the nonparametric Mann-Whitney test. All tests
were performed using the StatView 5.0 software (SAS Institute
Inc, Cary, NC).
Results
Production and characterization of recombinant Rift
Valley fever viruses
The generation of a recombinant RVFV expressing a green
fluorescent protein (GFP), rZHDNSs-GFP, has previously been
described [24]. Our previous attempts to generate a recombinant
RVFV expressing a humanized firefly luciferase (hFLuc) have
been confounded by genetic instability and the rapid emergence of
mutants with deletions [24]. Therefore, we generated rZHDNSs-
hRLuc RVFV that carries a humanized Renilla luciferase (hRLuc)
gene using Pol I based plasmids as previously described [24]. The
rescued rZHDNSs-hRLuc was amplified in Vero E6 cells and
stocks produced. The titer reached 86107 PFU/ml. The plaques
formed by rZHDNSs-hRLuc were fuzzy with a faint staining
inside, as those obtained with the rZHDNSs virus that carries a
deletion of the NSs gene [24]. To test the luciferase expression
within the infected cells, Vero E6 cells were infected with
rZHDNSs-hRLuc at a MOI of either 0.3 or 3, and lysed every
2 hours for 12 h. Luciferase activity was measured using
coelenterazine, a specific substrate of Renilla luciferase, and found
to be expressed at significant levels from 2 h post-infection
onwards, while uninfected Vero E6 cells showed no luciferase
activity. The luciferase activity increased with time and was
dependent on the MOI (data not shown). This is consistent with
previous reports [31,32]. To check the stability of the recombinant
virus in vitro, rZHDNSs-hRLuc was passaged on Vero E6 cells and,
at each passage, we measured the viral titer in the supernatant at
72 h post-infection and the luciferase activity within the infected
cells at 8 h post-infection with a MOI of 3. Both the viral titer and
the luciferase activity remained stable over at least 8 passages,
varying from 107 to 108 PFU/ml and from 107 to 108 raw light
units (RLU)/s per 36105 cells, respectively. To test the virulence
of the recombinant virus, wild-type 129S2/SvPas mice (N= 5) and
129S2/SvPas mice deficient for IFN-a/b receptor subunit 1
(Ifnar12/2) (N= 10) were infected i.p. with 104 PFU of rZHDNSs-
hRLuc. All wild-type mice survived the infection for 13 days with
no signs of disease, as seen following infection with rZHDNSs in
which the NSs gene is totally deleted [24] or Clone 13, a natural
isolate that lacks 69% of the NSs open reading frame [33]. In
contrast, all rZHDNSs-hRLuc infected Ifnar12/2 mice died within
45 h (Figure 1) from severe hepatitis with no signs of neurological
disorder. Infections of Ifnar12/2 mice with rZHDNSs or with
Clone 13 gave similar results ([24] and data not shown).
To evaluate the stability of the recombinant viruses in live
animals, total RNAs were extracted from the liver of rZHDNSs-
hRLuc- or rZHDNSs-GFP-infected Ifnar12/2 mice at 34 h post-
infection and RT-PCR assays were performed using primer pairs
flanking the hRLuc or GFP reporter gene. The amplification
product sizes were those expected from the structure of pPolI-
SZHDNSs-hRLuc and pPolI-SZHDNSs-GFP plasmids (data not
shown). No amplification products with smaller sizes were
observed, suggesting that the recombinant viruses maintained
their own genomic stability not only in cultured cells, but also
during in vivo infection. Furthermore, to examine the reporter
expression stability after in vivo infection, the recombinant
rZHDNSs-GFP was harvested from the liver of an infected
Ifnar12/2 mouse at 34 h post-infection and then used to infect
Vero E6 cells at a MOI of 1. The percentage of cells positive for
the N viral protein that were also GFP-positive was measured. The
percentage of N-positive, GFP-positive cells was almost identical to
Bioluminescence Imaging in Rift Valley Fever
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that of the initial viral stock (84%61.90% vs. 85%67.34%).
Altogether, these results suggest that the recombinant viruses were
stable for the time of infection in live mice.
Bioluminescence imaging for Rift Valley fever virus
infection
To visualize the spread of the virus, Ifnar12/2mice were infected
i.p. with 104 PFU of rZHDNSs-hRLuc. At 8, 16 and 34 h post-
infection, h-coelenterazine was injected i.p. This route of h-
coelenterazine administration was preferred to tail-vein injection
due to slower kinetics of light production, as previously reported
[39]. Mice were observed with real-time in vivo imaging 15 and
20 min after the injection of h-coelenterazine for the whole body
and the thorax, respectively. At 8 h post-infection, luminescence
was readily detected. Short integration periods (15 s) were sufficient
to acquire a significant signal. We observed strong signals between
the forelegs in the thoracic cavity, and below the xiphoid cartilage in
the abdominal cavity, respectively (Figure 2A). Imaging of the left
profile showed an additional signal in the spleen (Figure 2B). In
some experiments, animals were euthanized for ex vivo imaging, the
organs of the thorax and abdomen were harvested, and the
individual organs were imaged (Figure 2D). In the thorax, the
greatest signal originated from the thymus, whereas the signal from
the lungs was only slightly above background. In the abdomen, the
pancreas was the most luminescent organ. The spleen and the liver
also emitted significant luminescence. On average, a ten-fold higher
luminescence signal was observed in the harvested pancreas
compared to the liver. This suggests that the liver, the critical
target organ of the disease, was not among the main replication sites
for RVFV at this early stage of infection. At 16 h post-infection, the
whole body luminescence was higher than at 8 h post-infection
(Figure 2A). The signal spread out the abdominal cavity. The high
intensity of luminescence in the abdominal cavity precluded
detection in other locations unless integration was limited to the
thorax (Figure 2C). Dissection and ex vivo imaging showed a gradual
increase of luminescence in the pancreas and in the liver. Additional
sources of luminescence were the intestine mesentery, kidneys,
ovaries and uterus in females, the seminal vesicles, preputial glands,
epididymis and testis in males (Figure 2D, and data not shown). The
intensity of these signals was quite similar to that measured in the
spleen and in the liver (data not shown). At 34 h post-infection, the
intensity of the signal led to saturation of the camera using a 0.5 s
integration period, thus preventing identification of individual
organs (Figure 2A). Ex vivo imaging revealed that the highest signal
was in the liver. Other organs with intense luminescence were the
spleen, intestine mesentery and pancreas (data not shown).
Quantification of the luciferase expression in living mice during
the time course of infection showed that the luminescence signal
originated from the thymus remained constant from 8 h post-
infection onwards, whereas luminescence profiles were increased in
the liver and pancreas, suggesting a progressive increase of viral
replication in these organs (Figure 3).
To determine whether there was a correlation between the
luminescence detected by the camera and the amount of virus
genomes in the tissues, rZHDNSs-hRLuc-infected Ifnar12/2 living
mice were subjected to imaging. Next, the animals were
euthanized and the organs harvested and imaged. Total RNAs
were extracted from the organs and RVFV RNA copy numbers
were measured by quantitative real time RT-PCR. We observed a
highly significant correlation between the luminescence emitted by
the pancreas in living mice and RVFV RNA copy number
(Figure 4A). Similarly, luminescence intensity significantly corre-
lated with the RVFV RNA copy number in the harvested
pancreas, spleen and liver (Figure 4B–D).
The ability of h–coelenterazine to cross the blood-brain barrier
is unknown. To determine whether rZHDNSs-hRLuc can infect
the brain, we dissected and soaked the brain in an h-
coelenterazine solution and imaged (Figure 2D). At 8 h post-
infection, the luminescence intensity was ten-fold higher in the
brain from infected mice compared to control (104 photons/
second/cm2/steradian [p/sec/cm2/sr] vs. 103 p/sec/cm2/sr),
showing that the RVFV replicated in the brain at an early stage.
Light emission increased through 16 h and 34 h post-infection to
reach 76105 and 76106 p/sec/cm2/sr, respectively. Importantly,
the intensity of luminescence in the brain was ten- to hundred-fold
lower compared to the intensities in the thymus, pancreas, spleen,
liver, and intestine mesentery, suggesting that the viral load was
lower in the brain than in the thoracic and abdominal organs.
RVFV can be transmitted through injection of infectious saliva
from mosquito into the dermis or direct inhalation from body
fluids, such as blood of infected animals [2,3]. To approximate
these two natural routes of infection and to monitor their effects,
we compared the light production after intraperitoneal, intrader-
mal or intranasal inoculation of 104 PFU rZHDNSs-hRLuc into
Ifnar12/2 mice. Following intradermal inoculation of the ear
pinna (N= 5), luminescence was first visible in the neck on the side
of the injected ear, and in the abdominal cavity at 24 h post-
infection (Figure 5A). Histologic analysis established the source of
the light in the neck; the neck signal came from the lymph nodes
draining the injected ear (data not shown). At 40 h post-infection,
organs in the abdominal cavity, including the pancreas and the
liver were highly luminescent. All mice succumbed to infection by
69 h post-infection, a survival time significantly longer than after
i.p. inoculation (P,0.025). Luminescent virus inoculated intrana-
sally was already detected 24 h post-infection in the abdomen.
This mode of inoculation caused an interstitial pneumonia that
initiated as a distinctive luminescence signal in the lungs from 48 h
post-infection onwards (Figure 5B). Mice infected intranasally
(N= 5) survived significantly longer than after i.p. inoculation
(P,0.0047); all were dead by 69 h post-infection.
Identification of hematopoietic target cells by
immunohistochemistry and flow cytometry
To clarify the identity of the RVFV target cells, we carried out
histopathological analysis in RVFV-hRLuc-infected Ifnar12/2
Figure 1. Survival curve of mice challenged with rZHDNSs-
hRLuc RVFV. Ifnar1-deficient and wild-type mice were infected i.p.
with 104 PFU rZHDNSs-hRLuc virus. Mice were monitored twice daily for
4 days and, later, once daily for up to 13 days post-infection. Ifnar1-
deficient mice succumbed to disease between 40 and 50 hours post-
infection (N = 10). Wild-type 129S2/SvPas mice challenged with
rZHDNSs-hRLuc did not succumbed to infection (N= 5).
doi:10.1371/journal.pntd.0001421.g001
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mice at 8, 16 and 34 h after i.p. inoculation. No significant
histological lesions were observed at 8 and 16 h post-infection. By
contrast, at 34 h post-infection, moderate to marked lesions were
detected in the liver, lung, spleen, thymus, ovaries, and in the
mesentery surrounding the pancreas (Figure 6, data not shown).
No histological lesions were detected in the other organs. In the
liver, lung and spleen, the lesions were similar to those previously
reported in RVFV-infected wild-type mice [18,19,20,21]. Diffuse
apoptosis of lymphoid cells have been previously reported in areas
with or without RVFV antigen in the thymus of infected BALB/c
Figure 2. Replication sites of rZHDNSs-RLuc RVFV following inoculation via the intraperitoneal route. (A) Imaging of an Ifnar1-deficient
mouse after infection i.p. with 104 PFU rZHDNSs-hRluc. Imaging was performed at the indicated times post-infection. This image is representative of
thirteen mice. (B) Imaging of the left profile of a mouse at 8 h post-infection showing a bioluminescent signal in the spleen. This image is
representative of ten mice. (C) Imaging of the thorax at 16 h post-infection of the same mouse as in (A). Occulting the abdominal cavity revealed
bioluminescent signal in the thymus. (D) Ex vivo imaging after dissection at 8 and 16 h post-infection (T, thymus; Lg, lungs; P, pancreas; S, spleen; L,
liver; B, brain; I, intestines). Photographs were overlaid with false-color representations of bioluminescence intensity, measured in photons/s/cm2/sr
and indicated on the scales.
doi:10.1371/journal.pntd.0001421.g002
Figure 3. Luciferase levels of the liver, thymus and pancreas during the time course of infection. Five Ifnar1-deficient mice were infected
i.p. with 104 PFU rZHDNSs-hRLuc. Imaging of the liver (A), thymus (B) and pancreas (C) was performed in living mice at 8, 16 and 34 h post-infection
by defining regions-of-interests (ROIs). Results are given as photon/s/cm2/steradian and plotted as the mean and standard error of the mean of
photon counts over time.
doi:10.1371/journal.pntd.0001421.g003
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mice [21]. Accordingly, we identified the thymus as one of the
major targets of RVFV by bioluminescence. However, the
pancreas and reproductive organs were also luminescent although
none of these organs are known as tissue targets of RVFV.
Therefore, to identify cell types that support RVFV replication in
these organs, we studied tissue samples by histology and
immunohistochemistry with antibodies against the RVFV. In the
pancreas, no histological lesions were found in the exocrine or
endocrine components (Figure 6A). However, a multifocal
inflammatory lesion was observed in the mesentery around
pancreatic acini (peritonitis), characterized by necrosis of adipo-
cytes associated with infiltration of macrophages and neutrophils
(Figure 6A–C). Viral antigens were present only in the cytoplasm
of macrophages (Figure 6D) and, more rarely, in neutrophils
(Figure 6E), confirming that the virus did not target the pancreatic
exocrine or endocrine cells but macrophages. Similarly, in the
ovaries, viral nucleocapsid-positive macrophages were seen in the
stroma (Figure 6F). Thus macrophages appeared as important cell
targets for the replication of RVFV-hRLuc in Ifnar1-deficient
mice. To examine whether macrophages are also cell targets for
the replication of virulent RVFV in wild-type mice, histopatho-
logical and immunohistochemical analysis was performed in wild-
type 129S2/SvPas mice (N= 3) infected i.p. with 104 PFU ZH548.
Post-mortem analyses were carried out once mice displayed
clinical signs, i.e. three to five days after the inoculation.
Histopathological analysis of the pancreas and its mesentery
revealed no peritonitis. However, numerous macrophages con-
taining intracytoplasmic viral antigens were observed in the sinus
of the pancreaticoduodenal lymph node (Figure 6, G and H).
These macrophages occasionally displayed a hyperbasophilic and
condensed nucleus, a morphological change that is characteristic
for irreversible cell injury (Figure 6, I). Collectively, these results
confirmed that macrophages are important cell targets of the
RVFV in the mouse.
To further dissect target cells of RVFV replication in Ifnar1-
deficient mice, we used the recombinant virus rZHDNSs-GFP that
carries GFP in place of the NSs gene. We have shown previously
that cells infected in vitro with rZHDNSs-GFP are fluorescent upon
excitation at 488 nm [24]. Ifnar1-deficient mice were either
infected i.p. with 104 PFU rZHDNSs-GFP (N= 6) or mock-
treated (N= 5). At 24 h post-infection, the spleen was dissected
Figure 4. Emitted photons and viral RNA copy number in the pancreas, spleen and liver. Mice were infected i.p with 104 PFU rZHDNSs-
hRLuc. Bioluminescence imaging was performed at 8, 16 and 34 h post-infection. (A) Bioluminescence imaging of the pancreas was performed in
anesthetized mice. Subsequently, mice were euthanized and pancreas were harvested and further processed for determination of the viral RNA copy
number. (B–D) Mice were euthanized to harvest the pancreas, spleen and liver. The light emission was measured in the harvested pancreas (B), spleen
(C) and liver (D) by imaging. Each cross represents an individual organ. Results are given as the number of RNA copies per gram of organ (x axis) with
the y axis showing the flux expressed in p/s/cm2/sr. R2 and P indicate the correlation coefficient and the significance level, respectively.
doi:10.1371/journal.pntd.0001421.g004
Figure 5. In vivo replication sites of rZHDNSs-RLuc RVFV
following inoculation via intradermal or intranasal route. (A)
Representative image of luminescence in the lymph node (white
arrowhead) draining the right ear of Ifnar1-deficient mouse at 24 h after
intradermal inoculation of 104 PFU rZHDNSs-RLuc. (B) Luminescence
signal in the lungs (white arrowhead) at 48 h after intranasal inoculation
of 104 PFU rZHDNSs-RLuc. Images (A) and (B) are representative of five
mice. Photographs were overlaid with false colour representation of
bioluminescence intensity, measured in photon/s/cm2/sr and indicated
on the scales.
doi:10.1371/journal.pntd.0001421.g005
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and single-cell suspensions were analyzed by flow cytometry for
GFP expression. At this time point, 0.54% (range 0.14–1.53%) of
the total hematopoietic cell population of the spleen from
rZHDNSs-GFP-infected mice expressed GFP whereas no GFP-
positive cells were found in splenocytes after mock infection
(Figure 7A). We examined the expression of GFP in various
subsets of antigen presenting cells based on the surface expression
patterns of CD45.2, CD11b, CD11c, Ly6G, CD19, CD3, NKp46,
Figure 6. Lesions in the pancreas and expression of viral proteins in the pancreas and ovary. A–F: Histological lesions in Ifnar12/2 mice
infected i.p. with rZHDNSs-hRLuc RVFV. (A) Multifocal lesion centered on the mesentery, sparing the pancreatic tissue. (B) The expression of viral
proteins is seen in the mesentery exclusively (arrowheads). No viral immunolabeling is detected in the endocrine and exocrine components of the
pancreas (asterisks). (C) The lesion is characterized by necrosis of mesenteric adipocytes associated with infiltration of macrophages and neutrophils
that could be fragmented (suppuration). Note the presence of high number of cell debris in these lesions. (D) Macrophages in the mesentery
expressed viral antigens as seen by immunohistochemistry. (E) Neutrophils also expressed viral proteins. Almost all macrophages in the lesions were
infected by RVFV. By contrast, neutrophils expressing viral proteins were less numerous. (F) In the ovary, infected macrophages were multifocally
detected in the stroma. G–I: Lesions in wild-type 129S2/SvPas mice infected i.p. with ZH548 RVFV strain. (G–H) Multifocal macrophages expressing
viral protein were detected in the pancreaticoduodenal lymph node sinus (arrowheads). (I) Some of these macrophages displayed morphological
modifications suggesting irreversible injury, including a shrunken cytoplasm and a hyperbasophilic and fragmented nucleus. Hematoxylin and eosin
staining (A and C). Immunohistochemistry using antibodies directed against the RVFV (B, and D to I).
doi:10.1371/journal.pntd.0001421.g006
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CD115 and MHCII class II by multicolor flow cytometric analysis.
Among the CD11b+ CD115+ Ly6G2 (macrophages), CD11c+
CD11b+ MHC II+ (dendritic cells) [44] and CD11b+ CD11c2
Ly6G+ (granulocytes), on average 5.58% (range 2.15–8.71%),
4.5% (range 0.82–8.49%) and 1.96% (range 0.05–6.07%) cells
expressed GFP, respectively (Figure 7C [left panels], B [right
panels], and C [right panels], respectively). The percentage of
GFP-expressing cells within the total cell population of spleen
varied from one infected mice to another, indicating that the
dynamics of RVFV infection progression was not identical in all
individuals. However, each of the three subsets of immune cells
was infected with the same efficiency in the different mice. This is
shown by the fact that the ratio of GFP-expressing macrophages,
dendritic cells or granulocytes was highly correlated with the ratio
of GFP-expressing cells in the total cell population from the spleen
(Pearson correlation coefficient 0.97, 0.85 and 0.79, respectively).
These findings suggest a distinct pattern of susceptibility to
infection by the RVFV-GFP for different immune cells in the
following order: CD11b+ CD115+ Ly6G2 (macropha-
ges).CD11c+ CD11b+ MHC II+ (dendritic cells).CD11b+
CD11c2 Ly6G+ (granulocytes). On average, less than 0.4% (range
0–1.19%) of NKp46+ CD32 natural killer (NK) cells were positive
for GFP (Figure 7E, left panel). Finally, GFP fluorescence was seen
on average in only 0.25% (range 0.07–0.57%) of CD19+ CD32 (B
lymphocytes) cells and 0.20% (range 0.05–0.43%) NKp462 CD3+
(T lymphocytes) cells (Figure 7D and E, right panels). Thus, at
24 h post-infection, RVFV replicated in cells of the myeloid
lineage, primarily in mononuclear phagocytic cells, such as
macrophages, dendritic cells and granulocytes.
To study the significance of virus replication in phagocytic cells
in vivo, we injected intraperitoneally (i.p.) and intravenously (i.v.)
clodronate-loaded liposomes (CLL) to Ifnar1-deficient mice prior
to infection with RVFV. These liposomes are widely used to
deliver clodronate to phagocytic cells, especially macrophages, and
the accumulation of clodronate leads to irreversible metabolic
damages, which will eventually result in apoptosis [45]. As
reported previously [42,43], the i.p. administration of CLL kills
macrophages in the peritoneum and spleen of wild-type mice
whereas i.v. administration affects mainly macrophages in the
spleen and liver. We first analyzed the effect of CLL treatment on
the phagocytic cell population of the blood and spleen of Ifnar1-
deficient mice 24 h after i.p. and i.v. administration. Flow
cytometric analysis was performed to compare the percentage of
macrophages/monocytes, dendritic cells and granulocytes in
samples from mice treated with CLL (N=3) and PBS liposomes
(PBSL) (N=3). The CLL treatment resulted in a 23-fold reduction
of CD11b+ CD115+ cells (monocytes) and a 6-fold reduction of
CD11b+ F4/80+-expressing macrophages in the blood and spleen,
respectively. In addition, CD11b+ CD11c+ F4/802 cells (dendritic
cells) were decreased 9-fold in the blood. By contrast, CD11b+
CD11c2 Ly6G+ cells (granulocytes) were not depleted in the blood
and spleen, as previously reported [46]. Altogether this analysis
showed that, 24 h after CLL treatment, blood monocytes and
dendritic cells and spleen macrophages were efficiently depleted in
Ifnar1-deficient mice whereas granulocytes were not affected. Next,
CLL- or PBSL-treated mice were infected intradermally with
104 PFU rZHDNSs-hRLuc at 24 h after liposome administration.
To investigate whether the clodronate treatment affected viral
replication in vivo, we first observed PBSL- and CLL-administered
infected mice using the imaging of whole bodies at 24 and 40 h
post-infection. The profile of bioluminescence signals was similar
in PBSL- and CLL-administered mice (N= 5 in each group) (data
not shown). However, we observed weaker signals in CLL-
administered mice. Indeed, the signals in the liver region were on
average fifteen and four-fold lower at 24 and 40 h post-infection
respectively in CLL- administered mice compared to PBSL-
treated mice (P,0.05). We then measured the viraemia at 24 and
40 h post-infection in PBSL- and CLL-administered mice. At 24 h
post-infection, the CLL-administered mice (N= 3) displayed lower
blood plasma viral loads than the PBSL-treated mice (N= 3)
(4.0610362.96103 vs. 1.2610462.76103 PFU/ml, Mann-Whit-
ney test, P=0.0495). Similar observations were made at 40 h post-
infection (6.3610563.76105 vs. 2.6610762.26107 PFU/ml,
Mann-Whitney test, P=0.0495; P=0.0039 when data from both
time points were combined). Finally, the CLL-administered mice
(N= 12) survived for a longer period of time after challenge than
the PBSL-treated mice (N= 12) (Figure 8), suggesting that the
depletion of monocytes/macrophages and dendritic cells prior to
the viral infection affected the spreading and/or the containment
of viral infection into cells of other organs. The mice showed no
sign of encephalitis and succumbed to hepatitis. These observa-
tions confirmed the crucial role of monocytes/macrophages and
dendritic cells during RVFV infection in Ifnar12/2 mice.
Discussion
In vivo imaging studies using reporters, such as hRLuc and GFP,
may provide a more complete picture of the spatiotemporal
progression of a viral disease [47,48]. In this study, we report the
use of recombinant RVFV-hRLuc and RVFV-GFP strains to
investigate the in vivo dynamics of RVFV infection progression in
living mice and identify the virus-expressing cells. The recombi-
nant viruses were generated by replacing the NSs gene with the
reporter gene. Hence, these viruses were avirulent in immuno-
competent mice when compared with wild-type virus but they
were highly pathogenic in mice lacking interferon-a/b receptor,
enabling to use them for pathogenesis studies in this mouse model.
We were able to detect luciferase reporter expression at early
stages of infection in the main known sites of viral replication, the
liver, the spleen, the thymus and the brain [18,21,49,50,51]. The
pancreas appeared as an unexpected site of virus replication.
Using ex vivo imaging and histological examination, we primarily
identified macrophages infiltrating the adipose tissue surrounding
the pancreas as primarily virus-expressing cells. Similarly, RVFV-
expressing macrophages were identified in the stroma of the
ovary. The RVFV-GFP confirmed the importance of macro-
phages as specific host cells for the virus in Ifnar12/2 mice. It
further allowed the identification of dendritic cells and granulo-
cytes as target cells for RVFV replication. Interestingly, only a
low number of B-, T- and NK-cells expressed the GFP reporter.
Viral antigens have been previously detected in mononuclear
phagocytic cells and dendritic cells in the lymph nodes, spleen
and thymus from infected wild-type mice [21] and in macro-
phages in the lymph nodes from infected rats [51]. Interestingly,
Smith and colleagues [21] also noticed that lymphocytes did not
appear stained with the RVFV antibody in agreement with our
observations. Although RVFV replication in the human macro-
phage-like cell line U937 [52] and in cultured peritoneal
macrophages from susceptible rats [53] have been previously
documented, this is, to our knowledge, the first study to evaluate
the infection rates of various subsets of cells of the myeloid lineage
in vivo. Because the level of fluorescent GFP directly reflects the
extent of transcription and replication of the recombinant virus,
we assume that the virus is highly expressed in GFP-positive cells.
However, since macrophages, dendritic cells and granulocytes are
able to uptake cell debris, it is possible that some of these cells are
GFP-positive following phagocytosis of debris of RVFV-GFP-
infected cells in vivo.
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Phagocytic cells function as pathogen sensors. Macrophages and
neutrophils provide the first line of defense following infections.
Macrophages and dendritic cells are antigen presenting cells and
play a crucial role in the establishment of the adaptive immune
response. Infection with RVFV-GFP showed that phagocytic cells
are also target cells for RVFV. We investigated the importance of
the in vivo interaction between phagocytic cells and RVFV. We
treated Ifnar1-deficient 129S2/SvPas mice with CLL to deplete the
Figure 7. Expression of GFP reporter protein in splenocytes from RVFV-GFP-infected mice. Mice were either infected i.p. with 104 PFU
rZHDNSs-GFP or mock-treated (control) and euthanized 24 h after infection. Splenocytes of rZHDNSs-GFP-infected mice (lower plots) and control
(upper plots) were analyzed by flow cytometry for the expression of GFP. (A) Representative flow cytometry dot plots showing that CD45.2+ cells
(total hematopoietic cells) of an RVFV-GFP-infected mouse expressed GFP, as evaluated by fluorescence intensity (bottom plot). (B) Histogram
showing GFP expression in CD11c+ MHCII+ CD11b+ cells (dendritic cells). (C) Histograms showing GFP expression in Ly6G2 CD11b+ CD115+ cells
(macrophages) (left panels) and CD11b+ Ly6G+ (granulocytes) (right panels). (D) GFP expression was assessed in CD19+ CD32 cells (B lymphocytes). (E)
GFP expression in NKp46+ CD32 cells (NK cells) (left panels) and NKp462 CD3+ cells (T lymphocytes) (right panels). The data are representative of four
independent experiments. For each sample a total number of 100,000 to 450,000 splenic cells of infected animals was collected and analyzed. The
histograms show GFP expression in a total number of 1,700 dendritic cells, 1,500 macrophages, 1,600 granulocytes, 200,000 B lymphocytes, 3,000 NK
cells, and 100,000 T lymphocytes. *Normalized frequency of cells is the number of cells falling within each bin of the histogram; there are 256 bins for
each histogram.
doi:10.1371/journal.pntd.0001421.g007
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population of phagocytic cells, and showed that, following
intradermal infection with RVFV, the depleted mice allowed
reduced RVFV replication compared to control mice, as assessed
both by in vivo imaging and viral titration from blood samples.
Accordingly, CLL-treated mice displayed enhanced survival time
compared with control mice, indicating that phagocytic cells are
involved in the pathogenesis of RVF. Altogether, our data suggest
that during the initial stages of infection of Ifnar12/2 mice, the
virus replicates inside macrophages and dendritic cells. On the
other hand, since the RVFV replicates in diverse cell types in
peripheral tissues, the infection may progress rapidly and lead to
acute hepatitis and death.
RVFV is thought to be transmitted primarily by bites of infected
mosquitoes, by direct contact with infected body fluids or through
airborne transmission. It has been confirmed that exposure of mice
to aerosols containing RVFV is able to induce infection [54].
Following inoculation into a dermal site, RVFV-hRLuc expression
was seen in the draining lymph node which became the main site
of replication early after infection while the virus was still weakly
detected into the abdominal cavity. Later, virus spread and caused
severe hepatitis within 69 h post-infection. Following intranasal
inoculation, virus replicated in the lung where it caused
pneumonia within 48 h post-infection. Its dissemination to the
abdominal cavity was rapid and mice succumbed at 69 h post-
infection. Thus, typical routes of exposure were associated with
clear differences in the spatial and temporal progression of RVFV
and caused delayed death compared with i.p. inoculation.
Type I interferons (IFNs) are essential elements during host
antiviral defense [55]. Both recombinant RVFV strains inoculated
i.p. were able to kill Ifnar1-deficient 129S2/SvPas mice within 2
days whereas wild-type 129S2/SvPas mice survived infection,
indicating that a functional IFN-a/b pathway is critical for the
protection of mice from fatal infection with these attenuated
viruses. We showed that the recombinant viruses could replicate in
known target tissues and cells of RVFV. It is not clear whether in
the absence of the IFN-a/b receptor, the reporter RVFV can
replicate in tissues and cells that are not normally susceptible to
infection with a fully virulent RVFV in wild-type mice. Hence, we
infected wild-type 129S2/SvPas with the virulent RVFV ZH548
strain and observed infected macrophages in the spleen and
pancreaticoduodenal lymph node. However, we failed to identify
the peritonitis seen repeatedly in recombinant RVFV-infected
Ifnar12/2 mice. This suggests that, in Ifnar12/2 mice, cells of the
macrophage lineage displayed an increase susceptibility to RVFV
compared to wild-type mice. The high susceptibility of cells of the
macrophage/dendritic lineage to viral infection in the absence of a
functional type I IFN system has been previously observed. An
increased infection of cells of the macrophage/dendritic lineage
was observed in Ifnar12/2 mice infected with either the Sindbis
virus [56], or the mouse hepatitis virus [57]. Similarly,
macrophages showed the greatest increase in susceptibility among
the different splenocyte populations in West Nile virus-infected
Ifnar12/2 mice compared to wild-type mice [58]. More generally,
an increase in the replication of viruses in tissues and cells
normally susceptible to virus infection has been previously
observed in Ifnar12/2 mice. Coxsackievirus replicated dramati-
cally in the liver of Ifnar1-deficient compared with wild-type mice
[59]. Finally, previous investigation of poliovirus replication sites in
infected Ifnar12/2 mice expressing the human poliovirus receptor
showed that nontarget tissues became potentially permissive for
virus infection when IFNa/b signaling was disrupted [60].
Therefore, the fact that Ifnar12/2 mice inoculated with NSs-
deficient RVFV strains develop acute hepatitis and eventually die,
as wild-type mice infected with a virulent RVFV strain, does not
mean that the exact mechanisms of the cellular pathogenesis are
the same in Ifnar12/2 and wild-type mice. Thus, although Ifnar12/2
mice have proven to be a tractable system in which to study the
progression of RVFV infection in vivo, the immunocompromised
nature of this mutant strain remains a limitation in translating these
results directly to wild-type mice. Additional work needs to be done
to develop similar whole-organ imaging and flow cytometry analysis
in immune-competent mice. Further studies involving the use of
fully virulent RVFV – i.e. carrying the NSs gene – which express a
reporter gene, might allow us to give a comprehensive picture of the
dynamics of natural infection in mammals. Our work provides the
basis for the use of bioluminescent and fluorescent RVFV to study
the effects of specific mutations in the viral genome and of host
genetic factors on the tissue tropism and replication kinetics in living
mice.
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